-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $24

Benzinga·11/10/2026 13:04:04
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $21 to $24.